Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DNLI Denali Therapeutics Inc.

Market Closed 12-12 16:00:00 EST

17.98

+0.61

+3.51%

盘后17.70

-0.28-1.56%

17:11 EST

High18.30	Low17.24	Vol1.40M
Open17.41	D1 Closing17.37	Amplitude6.10%
Mkt Cap2.80B	Tradable Cap2.55B	Total Shares156.00M
T/O25.18M	T/O Rate0.99%	Tradable Shares142.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":17.98,"timestamp":1765573200000,"preClose":17.37,"halted":0,"volume":1400507,"hourTrading":{"tag":"盘后","latestPrice":17.7,"preClose":17.98,"latestTime":"17:11 EST","volume":66350,"amount":1192942.04,"timestamp":1765577499570},"delay":0,"floatShares":142000000,"shares":156000000,"eps":-2.91138,"marketStatus":"Market Closed","change":0.61,"latestTime":"12-12 16:00:00 EST","open":17.41,"high":18.3,"low":17.24,"amount":25180183.122338,"amplitude":0.061025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.91138,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1512709200000,"exchange":"NASDAQ","adjPreClose":17.37,"preHourTrading":{"tag":"盘前","latestPrice":17.39,"preClose":17.37,"latestTime":"09:27 EST","volume":720,"amount":12574.044720000002,"timestamp":1765549630049},"postHourTrading":{"tag":"盘后","latestPrice":17.7,"preClose":17.98,"latestTime":"17:11 EST","volume":66350,"amount":1192942.04,"timestamp":1765577499570},"volumeRatio":0.5029929095556254,"impliedVol":0.9056,"impliedVolPercentile":0.84},"requestUrl":"/m/hq/s/DNLI","defaultTab":"news","newsList":[{"id":"2590058048","title":"Denali Therapeutics Shares Fall in Premarket on Share Offering Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2590058048","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590058048?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:50","pubTimestamp":1765374600,"startTime":"0","endTime":"0","summary":"Denali Therapeutics shares were lower in premarket trading Wednesday after it priced its share offering below current trading levels.Shares were down 9.7% ahead of the morning bell at $17.75.The biotechnology company said it will offer 9.1 million shares at a price of $17.50 apiece.The stock has been under pressure in 2025, falling about 3.5% since the year began, and about 20% over the past 52 weeks.The company also issued prefunded warrants to purchase 2.3 million shares at a stock price of $17.49.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4535","BK4548","LENZ","BK4007","DNLI","BK4139"],"gpt_icon":0},{"id":"2590088823","title":"BRIEF-Denali Therapeutics Says Co Prices Public Offering Of 9.14 Mln Shares At $17.50 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2590088823","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590088823?lang=en_us&edition=fundamental","pubTime":"2025-12-10 13:18","pubTimestamp":1765343921,"startTime":"0","endTime":"0","summary":"BRIEF-Denali Therapeutics Says Co Prices Public Offering Of 9.14 Mln Shares At $17.50 EachDec 10 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA5J6P14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BK4139","DNLI"],"gpt_icon":0},{"id":"2590770370","title":"Denali Therapeutics Inc - Prices Public Offering of 9,142,857 Shares at $17.50 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2590770370","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590770370?lang=en_us&edition=fundamental","pubTime":"2025-12-10 13:14","pubTimestamp":1765343666,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA5J6P14:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","DNLI","BK4535"],"gpt_icon":0},{"id":"2590327584","title":"BUZZ-Denali Therapeutics slides after launching $200 million share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2590327584","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590327584?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:38","pubTimestamp":1765319930,"startTime":"0","endTime":"0","summary":"BUZZ-Denali Therapeutics slides after launching $200 million share sale** Drug developer Denali Therapeutics' DNLI.O shares slide 9% to $17.90 in extended trading** DNLI kicks off public offering of $200 million worth of shares and pre-funded warrants** Goldman Sachs, J.P. Morgan Securities, Morgan Stanley and Jefferies are joint book-running managers for offering** Proceeds will be used to advance commercial readiness and regulatory pathways for its drug pipeline, scale internal manufacturing capabilities, among other purposes** DNLI has 146.6 million outstanding shares as of September 30, according to prospectus** All 18 brokerages covering the stock rate it \"buy\" or higher; median PT $32 - data compiled by LSEG** As of last close, DNLI stock down 3.5% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL6N3XF0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU2237443465.HKD","LU0096364046.USD","LU1804176565.USD","LU1868837136.USD","LU0251142724.SGD","LU2750360641.GBP","LU0251131958.USD","LU0106831901.USD","LU2237443622.USD","IE0004086264.USD","BK4585","LU0742534661.SGD","LU2265009873.SGD","LU2237438978.USD","LU2237443382.USD","DNLI","IE00BSNM7G36.USD","LU2471134879.HKD","BK4588","IE0034235188.USD","BK4535","LU2237443895.HKD","BK4550","LU1791807156.HKD","LU1868836591.USD","BK4516","LU2750360997.AUD","IE00B19Z3B42.SGD","LU0061475181.USD","LU1868837300.USD","LU2471134523.USD","BK4127","LU1894683348.USD","LU2237443978.SGD","LU2471134952.CNY","IE0002270589.USD","LU1894683264.USD","BK4533","IE00B19Z3581.USD","LU2237443549.SGD","BK4552","BK4139","LU1868836914.USD","LU1868836757.USD","LU2471134796.USD","LU1668664300.SGD","LU0345770993.USD","LU0345770308.USD","BK4548"],"gpt_icon":0},{"id":"2590321079","title":"Denali Therapeutics: to Offer & Sell $200 Mln of Shares of Its Common Stock and, in Lieu of Common Stock to Certain Investors, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590321079","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590321079?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA3ZZKZR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNLI","BK4139","BK4535","BK4548"],"gpt_icon":0},{"id":"2590032103","title":"Denali Therapeutics Inc - Grants Underwriters Option for $30 Mln Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590032103","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590032103?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA3ZZKZR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNLI","BK4548","BK4139","BK4535"],"gpt_icon":0},{"id":"2590324002","title":"Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590324002","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590324002?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:01","pubTimestamp":1765314060,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec.  09, 2025  (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202767/0/en/Denali-Therapeutics-Announces-Proposed-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710400.SGD","LU0795875169.SGD","LU0106831901.USD","LU1668664300.SGD","LU2133065610.SGD","LU2271345857.HKD","BK4007","BK4534","LU1244550577.SGD","LU2089283258.USD","LU2089284900.SGD","LU1363072403.SGD","LU0158827948.USD","LU1074936037.SGD","LU1989772923.USD","LU0158827781.USD","LU2023251221.USD","BK4535","BK4588","LU1732799900.SGD","DNLI","BK4516","LU2347655156.SGD","LU0528227936.USD","LU0971096721.USD","BK4127","LU0225283273.USD","LU1244550221.USD","LU1791710582.SGD","IE00BZ1G4Q59.USD","LENZ","LU2111349929.HKD","BK4504","LU0320765646.SGD","LU0882574139.USD","IE00BKVL7J92.USD","LU1244550494.USD","LU1548497426.USD","LU1732800096.USD","LU1720051017.SGD","BK4139","LU0267386448.USD","LU0557290698.USD","LU0912757837.SGD","LU2028103732.USD","LU0314104364.USD","LU1720051108.HKD","LU0795875086.SGD","LU0234570918.USD","BK4539"],"gpt_icon":0},{"id":"2589981924","title":"Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start","url":"https://stock-news.laohu8.com/highlight/detail?id=2589981924","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589981924?lang=en_us&edition=fundamental","pubTime":"2025-12-06 00:49","pubTimestamp":1764953340,"startTime":"0","endTime":"0","summary":"FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/05/FDA.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/05/FDA.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/12/49235359/denali-flags-minimal-delay-after-fda-halts-rare-disease-trial-start","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/12/49235359/denali-flags-minimal-delay-after-fda-halts-rare-disease-trial-start","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4535","BK4007","BK4139","DNLI","IND","RPRX","BK4548"],"gpt_icon":0},{"id":"2588488474","title":"Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588488474","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588488474?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:06","pubTimestamp":1764853560,"startTime":"0","endTime":"0","summary":"Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.The companies said Thursday that the agreement is subject to various closing conditions. These include Denali receiving accelerated approval from the U.S. Food and Drug Administration for the treatment. A biologics license application for the accelerated approval of the treatment is currently under review by the FDA.Under the deal, Royalty Pharma would make an initial $200 million payment at the closing, as well as an additional $75 million payment if the treatment is approved by the European Medicines Agency by Dec. 31, 2029.In exchange, Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa from Denali.The royalty payments would cease upon reaching a 3x multiple, or 2.5x multiple if achieved by the first quarter of 2039, the companies said.Royalty Pharma Chief Executive Pablo Legorreta said the company is \"thrilled to esta","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","RPRX","BK4548","DNLI","LENZ","BK4139","BK4535"],"gpt_icon":0},{"id":"2588288964","title":"Denali Therapeutics Inc - Royalty Pharma to Receive 9.25% Royalty on Worldwide Sales of Tividenofusp Alfa From Denali","url":"https://stock-news.laohu8.com/highlight/detail?id=2588288964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588288964?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA30ZTCF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RPRX","BK4007","DNLI","BK4548","BK4535","BK4139"],"gpt_icon":0},{"id":"2588889672","title":"Press Release: Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889672","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588889672?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849600,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025  -- Denali Therapeutics Inc.  and Royalty Pharma plc  today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.\"We are delighted to partner with Denali and acquire a royalty on tividenofusp alfa, an innovative therapy that addresses a significant unmet need in the cognitive and physical manifestations of Hunter syndrome,\" said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. \"Denali's technology platform delivers therapeutics across the blood-brain barrier and is a promising new approach to brain diseases. We are thrilled to establish a relationship with Denali and believe tividenofusp alfa is a potential practice-changing therapy that could transform the lives of patients with Hunter syndrome.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","EMA","BK4007","LENZ","BK4588","BK4604","BK4139","DNLI","BK4539","TM","BK4548","03160","BK4555","BK4099","BK4081"],"gpt_icon":0},{"id":"2588770547","title":"Denali Therapeutics Drops Amid Volume Surge, Last Down 6.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588770547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588770547?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:19","pubTimestamp":1764616788,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL6N3X70YF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BK4548","DNLI"],"gpt_icon":0},{"id":"2584669929","title":"Denali Therapeutics Q3 Operating Expenses USD 137.434 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584669929","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584669929?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571483,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Denali Therapeutics Q3 operating income USD -137.434 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:01:49.883 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1LcbYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","BK4548","BK4139","BK4535"],"gpt_icon":0},{"id":"2584967389","title":"Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2584967389","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584967389?lang=en_us&edition=fundamental","pubTime":"2025-11-18 01:38","pubTimestamp":1763401110,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals (CNTA), CG Oncology (CGON) and Contineum Therapeutics (CTNM) delivered a series of clinical and financial updates in Q3, standing out as key outperformers on rising confidence","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","LU1732799900.SGD","LU0267386448.USD","LU2347655156.SGD","LU2133065610.SGD","IE00B3QW5Z07.USD","LU2028103732.USD","LU0098860793.USD","LU0106831901.USD","LU0557290698.USD","LU1732800096.USD","CTNM","IE00BGHQF748.EUR","LU0006306889.USD","LU2023251221.USD","DNLI","LU2111349929.HKD","LU0882574139.USD","LU1074936037.SGD","BK4585","LU1162221912.USD","IE00B64PRP62.GBP","LU1244550494.USD","LU0795875086.SGD","CNTA","LU1244550577.SGD","BK4504","BK4139","IE00BZ1G4Q59.USD","LU1244550221.USD","LU0234570918.USD","BK4007","BK4611","BK4534","BK4516","IE00BKVL7J92.USD","LU1989772840.SGD","BK4609","LU0795875169.SGD","BK4535","BK4539","LU1720051108.HKD","LU2089284900.SGD","CGON","LU0106261372.USD","BK4127","LU0971096721.USD","LU1720051017.SGD","LU1668664300.SGD"],"gpt_icon":1},{"id":"2583910662","title":"Can Denali Therapeutics (DNLI)’s New Leadership Steady the Narrative Amid Mounting Losses?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583910662","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583910662?lang=en_us&edition=fundamental","pubTime":"2025-11-16 19:21","pubTimestamp":1763292066,"startTime":"0","endTime":"0","summary":"Denali Therapeutics recently announced significant leadership changes, with Chief Medical Officer Carole Ho departing for Eli Lilly, Peter Chin appointed as Acting Chief Medical Officer, and seasoned executive Tim Van Hauwermeiren joining the Board of Directors.\nThese executive transitions come as the company reported higher net losses for both the third quarter and nine months ended September 30, 2025, increasing market attention on Denali’s future direction and stability.\nWe’ll explore how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/can-denali-therapeutics-dnlis-new-leadership-steady-the-narr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/can-denali-therapeutics-dnlis-new-leadership-steady-the-narr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","BK4139","BK4535","DNLI"],"gpt_icon":0},{"id":"1197631610","title":"Stock Track | Denali Therapeutics Soars 5.33% Pre-Market on Oppenheimer's Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1197631610","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197631610?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:49","pubTimestamp":1762786155,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. (DNLI) stock is soaring 5.33% in pre-market trading on Monday, following Oppenheimer analyst Jay Olson's reaffirmation of a Buy rating for the company. The analyst has set a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DNLI"],"gpt_icon":0},{"id":"2582724018","title":"Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582724018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582724018?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:18","pubTimestamp":1762784285,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson maintained a Buy rating on Denali Therapeutics today and set a price target of $35.00. According to TipRanks, Olson i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-denali-therapeutics-dnli-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-denali-therapeutics-dnli-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","DNLI"],"gpt_icon":0},{"id":"2581028255","title":"Denali Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Timothy Van Hauwermeiren","url":"https://stock-news.laohu8.com/highlight/detail?id=2581028255","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581028255?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:16","pubTimestamp":1762478193,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Timothy Van Hauwermeiren as a Director and the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL1jBWkg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","DNLI","BK4535"],"gpt_icon":0},{"id":"2581045849","title":"Denali Therapeutics Q3 net loss widens to $126.9 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045849","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045849?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:40","pubTimestamp":1762465221,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Q3 net loss widens to $126.9 mlnOverviewDenali Q3 net loss widens to $126.9 mln from $107.2 mln last yearOperating expenses increased due to R&D and commercial launch preparationsF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","BK4535","DNLI"],"gpt_icon":0},{"id":"2581017054","title":"Denali Therapeutics reports third quarter net loss of $126.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581017054","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581017054?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:06","pubTimestamp":1762463185,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. reported a net loss of $126.9 million for the third quarter ended September 30, 2025, compared to a net loss of $107.2 million for the same period in 2024. Total research and development expenses were $102.0 million, up from $98.2 million in the prior year quarter, with increases driven by new operations at the company's large molecule manufacturing facility in Salt Lake City, Utah. The company highlighted continued engagement with the FDA regarding the tividenofusp alfa BLA review for MPS II and completed enrollment in the DNL126 Phase 1/2 study for MPS IIIA. Denali also submitted regulatory applications to begin clinical studies with DNL628 for Alzheimer's disease and DNL952 for Pompe disease. Leadership changes include Peter Chin, M.D., assuming the role of Acting Chief Medical Officer following the departure of Carole Ho, M.D.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLBVYF7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","DNLI","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0992},{"period":"1month","weight":0.0263},{"period":"3month","weight":0.2671},{"period":"6month","weight":0.2357},{"period":"1year","weight":-0.2339},{"period":"ytd","weight":-0.1178}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.037766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.022228},{"month":3,"riseRate":0.25,"avgChangeRate":-0.087093},{"month":4,"riseRate":0.625,"avgChangeRate":0.0118},{"month":5,"riseRate":0.75,"avgChangeRate":0.047446},{"month":6,"riseRate":0.625,"avgChangeRate":0.059984},{"month":7,"riseRate":0.375,"avgChangeRate":-0.046178},{"month":8,"riseRate":0.625,"avgChangeRate":0.067423},{"month":9,"riseRate":0.5,"avgChangeRate":0.021936},{"month":10,"riseRate":0.375,"avgChangeRate":-0.037447},{"month":11,"riseRate":0.625,"avgChangeRate":0.13715},{"month":12,"riseRate":0.375,"avgChangeRate":0.020471}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction